• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acelyrin Inc (NQ: SLRN )

    3.770 -0.130 (-3.33%)
    Streaming Delayed Price Updated: 1:17 PM EDT, Jun 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 372,154
    Open 3.850
    Bid (Size) 3.760 (188)
    Ask (Size) 3.780 (9)
    Prev. Close 3.900
    Today's Range 3.670 - 3.890
    52wk Range 3.890 - 29.88
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
    From ACELYRIN, INC.
    Via GlobeNewswire

    Performance

    YTD
    -52.52%
    -52.52%
    1 Month
    -6.91%
    -6.91%
    3 Month
    -43.31%
    -43.31%
    6 Month
    -51.54%
    -51.54%
    1 Year
    -84.23%
    -84.23%

    More News

    Read More
    ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
    Via InvestorPlace
    SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
    Via InvestorPlace
    ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Leadership Transition
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
    From ACELYRIN, INC.
    Via GlobeNewswire
    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
    From Avalo Therapeutics
    Via GlobeNewswire
    Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
    Via Benzinga
    ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
    From ACELYRIN, INC.
    Via GlobeNewswire
    Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
    Via Benzinga
    ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
    From ACELYRIN, INC.
    Via GlobeNewswire
    ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
    From ACELYRIN, INC.
    Via GlobeNewswire
    Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    ACELYRIN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    SLRN IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    SLRN DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses in Excess of $100k to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acelyrin, and Beauty Health and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    SLRN IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
    Via NewMediaWire
    Topics Lawsuit
    Exposures Financial Legal
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.